Pfizer-Backed VitaDAO Votes on Creating For-Profit Company to Fund Longevity Research

The DAOs native token, VITA, rose 3% on news the community was considering the proposal.

AccessTimeIconApr 5, 2023 at 3:46 p.m. UTC
Updated May 9, 2023 at 4:12 a.m. UTC

Members of Pfizer-backed VitaDAO are voting on whether to create a for-profit company to secure and distribute funding for longevity research, the collective tweeted on Wednesday.

The company, to be called VitaTech, would leverage public funding to license longevity technologies developed in U.S. universities and support their continued development. The funds would come from research foundations and government grants such as the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR).

“To make up for [VitaDAO’s funding] shortfall, we are currently discussing a proposal to establish a for-profit US-based company that will bridge the gap between research and commercialization,” the collective tweeted.

The company will operate as a subsidiary or affiliate of VitaDAO. It also aims to serve as a launchpad for startups, helping research grant holders commercialize their tech, according to the proposal.

The proposal will enter a 10-week execution phase between April 3 and June 12, 2023, if approved.

VitaDAO raised $4.1 million in a funding round led by Pfizer Ventures with participation from several other investors in January. Pfizer is the first pharmaceutical company to weigh in on decentralized autonomous organization proposals and participate in the VitaDAO project’s incubation and commercialization.

VITA inched up 3% in the past 24 hours, according to CoinDesk data.

Edited by James Rubin.


Please note that our privacy policy, terms of use, cookies, and do not sell my personal information has been updated.

The leader in news and information on cryptocurrency, digital assets and the future of money, CoinDesk is a media outlet that strives for the highest journalistic standards and abides by a strict set of editorial policies. CoinDesk is an independent operating subsidiary of Digital Currency Group, which invests in cryptocurrencies and blockchain startups. As part of their compensation, certain CoinDesk employees, including editorial employees, may receive exposure to DCG equity in the form of stock appreciation rights, which vest over a multi-year period. CoinDesk journalists are not allowed to purchase stock outright in DCG.

CoinDesk - Unknown

Elizabeth Napolitano is a news reporter at CoinDesk.

Learn more about Consensus 2024, CoinDesk’s longest-running and most influential event that brings together all sides of crypto, blockchain and Web3. Head to to register and buy your pass now.

Read more about